Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$85.72

-0.14 (-0.16%)

, HAIN

Hain Celestial

$18.80

-0.38 (-1.98%)

09:11
12/12/18
12/12
09:11
12/12/18
09:11

Fly Intel: Pre-market Movers

HIGHER: Hain Celestial (HAIN), up 5% after announcing its board formed a special committee to consider strategic alternatives... United Rentals (URI), up 5% after providing FY18 and FY19 guidance at its investor day... DBV Technologies (DBVT), up 7% after its presentation of an oral abstract at the Skin Disease Summit.... Foamix (FOMX), up 12% after BofA Merrill Lynch analyst Jason Gerberry initiated the stock with a Buy and $11 price target citing de-risked dermatology assets. Gerberry said Foamix offers two late-stage drugs with efficacy that are competitive to existing therapies but offer a topical alternative to widely used oral minocycline, with less safety baggage as a systemically absorbed drug. UP AFTER EARNINGS: Pivotal Software (PVTL), up 1%. DOWN AFTER EARNINGS: Dave & Buster's (PLAY), down 13%. ALSO LOWER: Synergy Pharmaceuticals (SGYP), down 47% after the company announced an agreement with Bausch Health Companies (BHC), through which Bausch Health would acquire substantially all of Synergy's assets through Chapter 11 for $200M... eBay (EBAY), down 1% after Morgan Stanley analyst Brian Nowak downgraded eBay to Equal Weight from Overweight, stating that he had been wrong in his prior view about how quickly core marketplaces would deteriorate... Fluidigm (FLDM), down 5% after its 8.15M share secondary priced at $6.75 per share... Neurocrine Biosciences (NBIX), down 20% after its Phase IIb T-Force GOLD study for valbenazine in pediatric Tourette Syndrome did not meet its primary endpoint.

NBIX

Neurocrine

$85.72

-0.14 (-0.16%)

HAIN

Hain Celestial

$18.80

-0.38 (-1.98%)

URI

United Rentals

$101.89

0.02 (0.02%)

DBVT

DBV Technologies

$14.47

0.43 (3.06%)

FOMX

Foamix

$3.81

-0.19 (-4.75%)

PVTL

Pivotal Software

$17.80

-0.23 (-1.28%)

PLAY

Dave & Buster's

$51.08

-1.44 (-2.74%)

SGYP

Synergy Pharmaceuticals

$0.34

-0.0094 (-2.69%)

EBAY

eBay

$29.05

0.07 (0.24%)

FLDM

Fluidigm

$7.58

-0.11 (-1.43%)

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

  • 14

    Dec

  • 14

    Dec

  • 19

    Dec

  • 20

    Dec

  • 03

    Mar

  • 12

    Dec

NBIX Neurocrine
$85.72

-0.14 (-0.16%)

11/21/18
ADAM
11/21/18
INITIATION
Target $111
ADAM
Buy
Neurocrine initiated with a Buy at Canaccord
Canaccord analyst Sumant Kulkarni initiated Neurocrine with a Buy rating as he said the company is one of the few where a product launch exceeded expectations. He said he is guardedly optimistic heading into Phase 2b data for Ingrezza in pediatric Tourette syndrome and with the stock's recent pullback, he sees an attractive entry point. He also thinks the pullback could cause investors to look at Neurocrine to be involved in industry consolidation. Kulkarni set a $111 price target on Neurocrine shares.
11/15/18
BARD
11/15/18
NO CHANGE
Target $131
BARD
Outperform
Neurocrine elevated to Fresh Pick, FAERS fears unwarranted, says Baird
Baird analyst Brian Skorney elevated Neurocrine to Fresh Pick and said to take advantage of the unwarranted fear caused by the FDA's FAERS update. The analyst said the update was a regular update to their database and it did yield a numerically higher number of patient deaths. However, he said this is typical because as the number of Ingrezza prescriptions increase, so will the number of incidents. He believes this caused an overreaction and investors should take advantage of the buying opportunity. Skorney reiterated his Outperform rating and $131 price target on Neurocrine shares.
11/15/18
JEFF
11/15/18
NO CHANGE
Target $131
JEFF
Buy
Jefferies says buy Neurocrine after yesterday's 'unwarranted' selloff
Jefferies analyst Biren Amin tells investors to buy shares of Neurocrine Biosciences after hosting a dinner with management. Management shared thoughts on the Ingrezza launch and dispelled recent safety concerns, noting the company rigorously reports the majority of adverse events found in the FDA database and that none of the 88 deaths reported are due to Ingrezza, Amin tells investors in a research note. Further, the analyst thinks the risk/reward on shares into the December Tourettes data is "significant to the upside." Amin views yesterday's selloff as "unwarranted" and keeps a Buy rating on Neurocrine with a $131 price target. The stock closed yesterday down 13%, or $13.37, to $86.13.
12/12/18
STFL
12/12/18
NO CHANGE
STFL
Buy
Stifel would be buying Neurocrine on pullback after Tourette's failure surprise
After Neurocrine announced its Phase IIb T-Force GOLD study for valbenazine in pediatric Tourette Syndrome did not meet its primary endpoint, Stifel analyst Paul Matteis said he was " surprised and disappointed" by the study failure and admits he was wrong to have been optimistic with his 75% probability-of-success odds. He has previously written that Neurocrine shares could be down 15% on a negative study, but noted that was pinned to a higher valuation for the stock. In such a scenario, he would be buying the stock on weakness, said Matteis, who keeps a Buy rating on Neurocrine shares. In pre-market trading, the stock is down $15.24, or 18%, to $70.52.
HAIN Hain Celestial
$18.80

-0.38 (-1.98%)

11/12/18
LOOP
11/12/18
NO CHANGE
Target $24
LOOP
Hold
Hain Celestial price target lowered to $24 from $29 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Hain Celestial to $24 after its Q1 results, saying the 36% decline in EBITDA amid "increased trade spending, higher costs, and supply disruptions was bigger than he expected". The analyst notes that the company's new CEO should start to "focus on marketing spending on the best opportunities" within its brand portfolio, but expects this to be a "multi-year process". Wolf adds that although consumption trends have showed signs of improving, he sees Hain Celestial's near-term risk-reward as "balanced", keeping his Hold rating.
11/09/18
JEFF
11/09/18
NO CHANGE
Target $45
JEFF
Buy
Hain Celestial selloff yesterday a buying opportunity, says Jefferies
Jefferies analyst Akshay Jagdale attributes the selloff yesterday in shares of Hain Celestial to investor concerns of an earnings reset in February following the CEO's strategic review, especially "in light of the significant" second half improvement needed to meet fiscal 2019 guidance. The analyst estimates the market is pricing in 20% lower earnings than what management guiding to, or fiscal 2019 earnings per share in the range of 98c-$1.13 versus guidance of $1.21-$1.38. The analyst, however, views the concerns as overblown. The market seems to be of the view that Hain cannot simultaneously grow its sales and its margins over the long-term, Jagdale tells investors in a research note. He disagrees, however, and views yesterday's selloff as a buying opportunity. The analyst keeps a Buy rating on Hain Celestial with a $45 price target.
11/09/18
UBSW
11/09/18
NO CHANGE
Target $21
UBSW
Sell
Hain Celestial back half guidance at risk, says UBS
UBS analyst Steven Strycula said the arrival of Hain Celestial's new CEO may eventually change the narrative on the shares, but he believes the next few quarters will be needed to upgrade the talent, reassess investment spending, and review the sensibility of the company's portfolio scope. Strycula remains cautious because of the risk of an earnings reset and reiterated his Sell rating while lowering his price target to $21 from $25 on Hain Celestial shares.
10/12/18
PIPR
10/12/18
INITIATION
Target $26
PIPR
Neutral
Hain Celestial assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery assumed coverage of Hain Celestial with a Neutral rating and $26 price target. The analyst prefers better visibility on "sustainable top-line acceleration" before getting more constructive on the shares.
URI United Rentals
$101.89

0.02 (0.02%)

10/22/18
NRCS
10/22/18
UPGRADE
Target $49
NRCS
Buy
Northcoast upgrades Herc Holdings to Buy on 'overdone' selloff
Northcoast analyst John Healy upgraded Herc Holdings (HRI) to Buy from Neutral with a $49 price target. The 45% decline in shares since the July highs are largely the result of a "de-risking macro trade" as well as "less than hoped for rate trends" at competitor United Rentals (URI), Healy told investors earlier in a research note. The analyst views the selloff as "overdone" and believes Herc will "impress" when reporting results with a positive outlook.
10/23/18
STPT
10/23/18
INITIATION
Target $140
STPT
Buy
United Rentals initiated with a Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas initiated United Rentals with a Buy and $140 price target.
10/31/18
MSCO
10/31/18
NO CHANGE
Target $175
MSCO
Overweight
United Rentals shares 'too cheap to ignore,' says Morgan Stanley
Morgan Stanley analyst Courtney Yakavonis contends that United Rentals shares have become "too cheap to ignore" after falling nearly 45% since mid-September. She believes the market is underappreciating the potential for modest, but sustained, rate growth in 2019 as well as margin improvements. The stock is currently trading at a level typically only seen when United exhibits either negative organic revenue growth or during periods of declining non-residential growth, which is not the case, noted the investors. She maintains an Overweight rating on United Rentals shares with a $175 price target.
11/15/18
UBSW
11/15/18
NO CHANGE
Target $180
UBSW
Buy
United Rentals on a path of higher returns and growth, says UBS
UBS analyst Steven Fisher met with United Rentals management and came away confident the company is on a path of driving higher returns and profitable growth over the longer-term. He said demand remains solid in the medium-term and the customer-facing strategy is working. Fisher reiterated his Buy rating and $180 price target on United Rentals shares.
DBVT DBV Technologies
$14.47

0.43 (3.06%)

04/18/18
04/18/18
NO CHANGE
Target $37

Buy
Pediatric allergist sees both DBV, Aimmune winning approval, says Jefferies
Jefferies analyst Eun Yang hosted a discussion panel with a pediatric allergist who believes both both DBV Technologies' (DBVT) Viaskin Peanut and Aimmune's (AIMT) AR101 will be approved by the FDA. The allergist thinks Viaskin would be preferable due to its lower burden of monitoring and AR101 would be preferred due to its stronger efficacy, Yang tells investors in a research note. The doctor believes choice of treatment, if both are approved, will depend on a patients' goal of treatment and preference. Yang has a Buy rating on DBV Technologies with a $37 price target.
04/05/18
PIPR
04/05/18
NO CHANGE
Target $62
PIPR
Overweight
Piper reiterates Overweight on Aimmune after call with allergist
Piper Jaffray analyst Charles Duncan reiterates an Overweight rating on Aimmune Therapeutics (AIMT) with a $62 price target after speaking to a community-based allergist whose practice he feels is representative of the U.S. peanut allergy market. The analyst heard three key takeaways that reinforce his thesis for Aimmune's AR101 market potential: Both safety/tolerability are better than expected and completely feasible in most of his patients, several patient segments will likely prefer AR101 in his practice, and there is likely very high demand for any immunotherapy with community doctors likely to use both AR101 and DBV Technologies' (DBVT) Viaskin, if both are approved.
09/13/18
STFL
09/13/18
INITIATION
Target $35
STFL
Buy
DBV Technologies initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated DBV Technologies with a Buy rating and a price target of $35, saying the stock offers a "favorable" risk-reward over the next 12 months. Archila acknowledges investors' skepticism due to the Viaskin peanut missing its Phase 3 lower confidence level, but adds that his talks with regulatory experts suggest an over 50% probability that the Viaskin Biologic License Application will be accepted and yield an eventual approval.
08/20/18
JMPS
08/20/18
NO CHANGE
Target $30
JMPS
Outperform
DBV Viaskin Peanut BLA acceptance could be derisking event, says JMP Securities
After hosting meetings with Kevin Trapp, DBV Technologies' newly appointed Chief Commercial Officer, JMP Securities analyst Liisa Bayko noted the company is prepared to submit its BLA for Viaskin Peanut in October and she looks for acceptance 60 days later, which she said would be the first positive milestone for the company and could be a "meaningful derisking event." Viaskin Peanut is eligible for priority review and her expectation is that DBV will receive it, added Bayko, who reiterated her Outperform rating and $30 price target on the shares.
FOMX Foamix
$3.81

-0.19 (-4.75%)

10/12/18
10/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Comcast (CMCSA) reinstated with an Overweight at JPMorgan. 2. Abeona Therapeutics (ABEO) initiated with a Buy at Mizuho. 3. Foamix (FOMX) initiated with an Overweight at Cantor Fitzgerald. 4. Match Group (MTCH) and IAC (IAC) were initiated with a Buy at Nomura Instinet while Angi Homeservices (ANGI) was initiated with a Neutral at Nomura Instinet. 5. Terex (TEX) initiated with a Neutral at Longbow. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/18
COWN
11/07/18
NO CHANGE
Target $30
COWN
Outperform
Foamix sale now more likely after Phase 3 trial successes, says Cowen
Cowen analyst Ken Cacciatore said that after Foamix Pharmaceuticals announced a successful Phase 3 program evaluating FMX103 in the treatment of moderate-to-severe papulopustular rosacea on the heels of the Phase 3 success in acne, he believes strategic interest will now likely accelerate. He notes that management indicated that they don't think they need additional capital to execute on their filing strategy or initial launch, which is "the type of commentary" he interprets as potentially signaling a willingness to entertain a potential business development deal or outright sale. Given the value of recent deals in the space, Cacciatore added that he believes Foamix shares are "meaningfully undervalued." The analyst keeps an Outperform rating and $30 price target on Foamix.
12/04/18
HCWC
12/04/18
NO CHANGE
Target $12
HCWC
Buy
Foamix remains 'substantially undervalued,' says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Foamix Pharmaceuticals to $12 from $11 citing the positive top-line results from two pivotal Phase 3 clinical trials of FMX103 for the treatment of moderate-to-severe papulopustular rosacea. The analyst believes the high level of statistical significance underscores the degree of efficacy observed. He reiterates a Buy rating on Foamix and says the stock remains "substantially undervalued."
12/12/18
BOFA
12/12/18
INITIATION
Target $11
BOFA
Buy
Foamix initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated Foamix with a Buy and $11 price target citing de-risked dermatology assets. Gerberry said Foamix offers two late-stage drugs with efficacy that are competitive to existing therapies but offer a topical alternative to widely used oral minocycline, with less safety baggage as a systemically absorbed drug. The analyst thinks FMX-101 and -103 will take market share and build recognition in the "experience-driven derm space."
PVTL Pivotal Software
$17.80

-0.23 (-1.28%)

10/22/18
NEED
10/22/18
INITIATION
Target $25
NEED
Buy
Pivotal Software initiated with a Buy at Needham
Needham analyst Jack Andrews initiated Pivotal Software with a Buy and $25 price target.
12/12/18
NEED
12/12/18
NO CHANGE
Target $28
NEED
Buy
Pivotal Software price target raised to $28 from $25 at Needham
Needham analyst Jack Andrews raised his price target on Pivotal Software to $28 and kept his Buy rating after its "solid" Q3 results. The analyst notes that the demand for the company's platform is seen as "robust" with "more blue chip customers willing to adopt new technologies to become software-first". Andrews further cites the inflection in the platform usage patterns indicating that a "majority of development centers around modernization of legacy applications", making Pivotal Software a "vital bridge in an enterprise's transition" toward creating "value-added applications".
10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
IBM deal reinforces Morgan Stanley confidence in Hybrid Cloud emergence
After IBM (IBM) announced its intention to acquire Red Hat (RHT) for about $34B in a deal with an over 60% premium to Red Hat's Friday closing price, Morgan Stanley analyst Keith Weiss said the announcement reinforced both his confidence in the emergence of Hybrid Cloud architectures and the strength of IT spending into 2019. Red Hat has been Microsoft's (MSFT) primary competitor within server operating systems, and has generally been taking share, said Weiss, who thinks the longer-term opportunity or threat for Microsoft hinges on the ability of IBM to execute well and maintain the open source enthusiasm around the Red Hat distributions. For VMware (VMW) and Pivotal Software (PVTL), while Weiss sees little near-term impact, he adds that the proposed combination would likely result in a fiercer competitive environment going forward. For New Relic (NEWR), he sees little direct competitive impacts from the proposed merger. Given HortonWorks' (HDP) strong existing ties to IBM, Cloudera (CLDR) could benefit by becoming a preferred data management vendor within the OpenShift ecosystem, Weiss added.
10/23/18
NEED
10/23/18
INITIATION
NEED
Buy
Red Hat, Pivotal Software, ServiceNow initiated with a Buy at Needham
As reported earlier, Needham analyst Jack Andrews initiated Red Hat (RHT), Pivotal Software (PVTL), and ServiceNow (NOW) with Buy ratings as part of his broader research note on select cloud-driven infrastructure software companies. The analyst notes that he expects new proprietary applications to generate rapid growth of cloud-based workloads, making the "platform as a service", or PaaS, market "one of the fastest growing segments in the technology stack". Andrews also points out that in addition to allowing "enterprises to run machine learning and deep learning algorithms in order to glean insights on how to improve customer experiences", a unique characteristic of infrastructure software companies is their pricing model driven by "per compute" or "consumption basis". The analyst contends that this makes them an attractive investment as "an infrastructure software vendor can maintain a long tail of growth within an enterprise by continuing to add licenses". Andrews assigns Red Hat a price target of $183, Pivotal Software a target of $25, and ServiceNow a price target of $224.
PLAY Dave & Buster's
$51.08

-1.44 (-2.74%)

12/12/18
WELS
12/12/18
NO CHANGE
Target $59
WELS
Outperform
Dave & Buster's price target lowered to $59 from $69 at Wells Fargo
Wells Fargo analyst Jon Tower raised his price target for Dave & Buster's to $59 from $69, while reiterating an Outperform rating on the shares. The analyst notes that momentum that began to build in Q2 carried over into Q3 for its amusement business, but this performance was overshadowed by weaker-than-expected food and beverage same-store sales and what he views to be a conservative initial guide for FY19. Regarding the FY19 guidance, Tower thinks Dave & Buster is offering a conservative view of new-store productivity expectations.
12/12/18
PIPR
12/12/18
NO CHANGE
Target $64
PIPR
Overweight
Dave & Buster's selloff today a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Nicole Miller Regan recommends using today's post-earnings selloff in shares of Dave & Buster's as a buying opportunity. An inflection point back into positive comp territory "is on the horizon," Regan tells investors in a post-earnings research note. She says that looking through near-term noise, the lower-end of the company's fiscal 2018 guidance did tick higher while strategic initiatives across food and beverage, amusements, technology, and new store development categories appear on track. The analyst maintains an Overweight rating on Dave & Buster's with a $64 price target.
12/12/18
JEFF
12/12/18
NO CHANGE
Target $58
JEFF
Buy
Dave & Buster's price target lowered to $58 from $72 at Jefferies
Jefferies analyst Andy Barish lowered his price target for Dave & Buster's to $58 but keeps a Buy rating on the shares following the company's Q3 results. While guidance for 2019 implies slowing new store productivity, the stock is trading back down to 6 times estimated 2020 EBITDA, where it finds support, Barish tells investors in a post-earnings research note. He recommends buying Dave & Buster's for value and improving same-store-sales.
12/12/18
MAXM
12/12/18
NO CHANGE
Target $64
MAXM
Buy
Dave & Buster's price target lowered to $64 from $76 at Maxim
Maxim analyst Stephen Anderson lowered his price target on Dave & Buster's to $64 after its "mixed" Q3 results showing in-line EPS, strong new unit sales, and disappointing comps driven mainly by the miss in its Food & Beverage segment. The analyst adds that while the company raised the lower end of its FY18 guidance, its FY19 outlook was below consensus because of a "higher mix of new-to-market locations and higher labor costs". Anderson lowers his FY19 EPS view to $3.17 from $3.49 but maintains his Buy rating, anticipating Dave & Buster's expanded virtual reality gaming and "revamped value platform" to support its mid-teen EPS growth.
SGYP Synergy Pharmaceuticals
$0.34

-0.0094 (-2.69%)

10/26/18
ADAM
10/26/18
DOWNGRADE
ADAM
Hold
Synergy Pharmaceuticals downgraded to Hold from Buy at Canaccord
10/26/18
BTIG
10/26/18
DOWNGRADE
BTIG
Neutral
Synergy Pharmaceuticals downgraded to Neutral from Buy at BTIG
BTIG analyst Timothy Cheng downgraded Synergy Pharmaceuticals to Neutral after its update on its strategic review indicating that no entity is willing to "make a fair offer for the company". In a "worst case scenario outcome", Cheng added that the company has forecast its net Trulance sales for the treatment of IBS-C and chronic constipation to come in at $42M-$47M - below its $61M threshold set by term loan holder CRG. The analyst states that the near term for Synergy Pharmaceuticals "looks grim" and its options, including a "potential bankruptcy", look limited.
10/26/18
ADAM
10/26/18
DOWNGRADE
Target $2
ADAM
Hold
Synergy Pharmaceuticals downgraded to Hold at Canaccord
As reported previously, Canaccord analyst John Newman downgraded Synergy Pharmaceuticals to Hold from Buy. The analyst cited the company's guidance, which detailed slower than anticipated market growth leading to lower than expected revenues and the potential inability to fulfill the CRG debt covenant of roughly $61M in revenues in 2018. Newman lowered his price target to $2 from $13 on Synergy Pharmaceuticals shares.
01/25/18
BTIG
01/25/18
NO CHANGE
Target $7
BTIG
Buy
Synergy funding worries may be overdone, says BTIG
BTIG analyst Timothy Chiang noted that Synergy Pharmaceuticals (SGYP) announced that Trulance received expanded FDA approval for IBS-C, which puts it more on par with market leader Linzess from Ironwood (IRWD) and Allergan (AGN). He sees Trulance benefiting from increased payor access and believes the company will have sufficient cash in order to gain access to a second loan tranche of $100M expected by next month, stating that funding worries may be overdone. Chiang keeps a Buy rating and $7 price target on Synergy shares.
EBAY eBay
$29.05

0.07 (0.24%)

12/12/18
12/12/18
DOWNGRADE
Target $33

Equal Weight
Morgan Stanley admits to being wrong on marketplaces, cuts eBay to Equal Weight
As previously reported, Morgan Stanley analyst Brian Nowak downgraded eBay to Equal Weight from Overweight, stating that he had been wrong in his prior view about how quickly core marketplaces would deteriorate. He believes eBay's multiple remains linked to U.S. GMV growth, which is an issue as he projects 0%-1% U.S. GMV growth through the first half of 2019 and about 2% in full year 2019, Nowak tells investors. He expects this deceleration, and the U.S. business likely turning to contraction, driving near-term negative revisions and weighing on the multiple investors are willing to pay for eBay shares, Nowak added. He lowered his price target on eBay shares to $33 from $55.
12/12/18
MSCO
12/12/18
DOWNGRADE
MSCO
Equal Weight
eBay downgraded to Equal Weight from Overweight at Morgan Stanley
12/07/18
BARD
12/07/18
NO CHANGE
Target $41
BARD
Outperform
eBay tracker points to better sequential growth in November, says Baird
Baird analyst Colin Sebastian said in a note published before the open that his proprietary tracker of merchandise volume on eBay pointed to some improvement in year-over-year and sequential volume trends in November. The analyst, who previously highlighted sluggish October volume, said the new data leads him to believe eBay is likely on track for in-line to even slightly better Q4 results. He maintains a $41 price target and Outperform rating on eBay shares, which are up about 1% to $29.74 in early trading.
12/06/18
JMPS
12/06/18
NO CHANGE
Target $2050
JMPS
Outperform
Amazon lead highlighted in holiday shopping survey, says JMP Securities
Following the firm's recent survey of about 250 online shoppers, JMP Securities analyst Ronald Josey said the results of the polling make him incrementally confident in Amazon's (AMZN) ability to continue to take wallet share. The survey showed Amazon is the first shopping destination of 73% of respondents and it also revealed a Prime member base expansion compared to last year, noted Josey. Walmart (WMT), Target (TGT) and eBay (EBAY) were the other most often used e-commerce sites among respondents, the analyst noted. He keeps an Outperform rating and $2,050 price target on Amazon shares.
FLDM Fluidigm
$7.58

-0.11 (-1.43%)

11/02/18
PIPR
11/02/18
UPGRADE
Target $10
PIPR
Overweight
Fluidigm upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk upgraded Fluidigm to Overweight and raised his price target for the shares to $10 from $6.70. Mass Cytometry lead the beat in Q3 with both strong instrument placements and consumables growth while management remains confident on long-term adoption trends, Quirk tells investors in a post-earnings research note. The analyst is impressed with Mass Cytometry adoption and upgraded the shares to reflect that.

TODAY'S FREE FLY STORIES

MS

Morgan Stanley

$42.16

-0.24 (-0.57%)

07:21
01/24/19
01/24
07:21
01/24/19
07:21
Hot Stocks
Morgan Stanley CEO: Shutdown could have 'extremely damaging' impact »

Gorman is speaking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAH

Platform Specialty Products

$10.90

-0.15 (-1.36%)

07:19
01/24/19
01/24
07:19
01/24/19
07:19
Hot Stocks
Platform Specialty Products receives regulatory approval for Arysta sale »

Platform Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MB

Mindbody

$36.41

-0.19 (-0.52%)

07:19
01/24/19
01/24
07:19
01/24/19
07:19
Downgrade
Mindbody rating change  »

JMP downgrades Mindbody…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$205.77

2.77 (1.36%)

07:18
01/24/19
01/24
07:18
01/24/19
07:18
Upgrade
Palo Alto Networks rating change  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Feb

PG

Procter & Gamble

$94.87

4.37 (4.83%)

07:18
01/24/19
01/24
07:18
01/24/19
07:18
Recommendations
Procter & Gamble analyst commentary  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 03

    Mar

NMCI

Navios Maritime Containers

$3.03

(0.00%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Hot Stocks
Navios Maritime Containers exercises option to acquire containership for $52.5M »

Navios Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAPR

Capricor Therapeutics

$0.58

-0.0751 (-11.46%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Hot Stocks
Capricor Therapeutics announces HOPE-Duchenne trial results published »

Neurology, an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$95.49

-1.05 (-1.09%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

NESRF

Northern Star Resources

$0.00

(0.00%)

07:16
01/24/19
01/24
07:16
01/24/19
07:16
Downgrade
Northern Star Resources rating change  »

Northern Star Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
01/24/19
01/24
07:15
01/24/19
07:15
General news
FX Update: The dollar has posted advances »

FX Update: The dollar has…

EEX

Emerald Expositions Events

, RELX

RELX

$21.78

-0.03 (-0.14%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Recommendations
Emerald Expositions Events, RELX analyst commentary  »

Emerald Expositions a…

EEX

Emerald Expositions Events

RELX

RELX

$21.78

-0.03 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$94.87

4.37 (4.83%)

, EL

Estee Lauder

$126.94

1.19 (0.95%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Recommendations
Procter & Gamble, Estee Lauder, Church & Dwight analyst commentary  »

P&G report has…

PG

Procter & Gamble

$94.87

4.37 (4.83%)

EL

Estee Lauder

$126.94

1.19 (0.95%)

CHD

Church & Dwight

$65.45

-0.7 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 05

    Feb

  • 18

    Feb

  • 03

    Mar

  • 28

    May

USAP

Universal Stainless & Alloy

$14.62

-0.515 (-3.40%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Hot Stocks
Universal Stainless & Alloy increases low alloy VAR bar base price 5%-10% »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

07:12
01/24/19
01/24
07:12
01/24/19
07:12
Recommendations
Xilinx analyst commentary  »

Xilinx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CNOB

ConnectOne Bancorp

$20.08

-0.19 (-0.94%)

07:11
01/24/19
01/24
07:11
01/24/19
07:11
Earnings
ConnectOne Bancorp reports Q4 adj. EPS 59c, consensus 55c »

As of December 31, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AEP

American Electric

$77.00

0.65 (0.85%)

07:11
01/24/19
01/24
07:11
01/24/19
07:11
Earnings
Breaking Earnings news story on American Electric »

American Electric backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AEP

American Electric

$77.00

0.65 (0.85%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Earnings
American Electric reports Q4 EPS 74c, consensus 71c »

Reports Q4 revenue $3.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

LVS

Las Vegas Sands

$57.25

0.26 (0.46%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Recommendations
Las Vegas Sands analyst commentary  »

Las Vegas Sands price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

CNCE

Concert Pharmaceuticals

$14.02

-0.26 (-1.82%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Hot Stocks
Concert Pharmaceuticals initiates Phase 1 single-ascending dose trial of CTP-692 »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 30

    Jan

  • 12

    Feb

  • 13

    Feb

MDR

McDermott

$8.49

0.01 (0.12%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Hot Stocks
McDermott announces ethylene furnace award in Indonesia »

McDermott announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

BWB

Bridgewater Bancshares

$10.41

-0.17 (-1.61%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Earnings
Bridgewater Bancshares reports Q4 EPS 25c, two est. 23c »

The fourth quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDC

China Lending Corp.

$1.11

-0.005 (-0.45%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Hot Stocks
China Lending Corp. acquires minority interest in financial service company »

China Lending Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

RCI

Rogers Communications

$54.51

-0.12 (-0.22%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Earnings
Rogers Communications sees FY19 revenue up 3%-5% »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

LIVX

LiveXLive Media

$6.25

-0.05 (-0.79%)

07:08
01/24/19
01/24
07:08
01/24/19
07:08
Recommendations
LiveXLive Media analyst commentary  »

LiveXLive Media price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRIS

Curis

$1.06

-0.045 (-4.09%)

07:08
01/24/19
01/24
07:08
01/24/19
07:08
Hot Stocks
Curis says first mesothelioma patient dosed in CA-170 study »

Curis announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.